Comparison of weekly and daily recall of pain as an endpoint in a randomized phase 3 trial of cabozantinib for metastatic castration-resistant prostate cancer

INTRODUCTION: Scant evidence reveals whether the use of weekly versus daily pain ratings leads to meaningful differences when measuring pain as a clinical trial outcome. We compared the ability of weekly ratings and descriptors of daily ratings to evaluate pain as an endpoint in a randomized phase 3...

Descripción completa

Detalles Bibliográficos
Autores principales: Schaffer, Elisabeth M, Basch, Ethan M, Schwab, Gisela M, Bennett, Antonia V
Formato: Online Artículo Texto
Lenguaje:English
Publicado: SAGE Publications 2021
Materias:
Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8290982/
https://www.ncbi.nlm.nih.gov/pubmed/33884929
http://dx.doi.org/10.1177/17407745211009547

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8290982/
https://www.ncbi.nlm.nih.gov/pubmed/33884929
http://dx.doi.org/10.1177/17407745211009547

Ejemplares similares